article thumbnail

Texas Invests $50M in Psychedelic Drug Research into Ibogaine to Treat Addiction

Drugs.com

MONDAY, June 16, 2025 — Texas has moved to fund research into ibogaine, a psychedelic drug that may help treat addiction, depression, and brain injuries. Greg Abbott signed a bill last week approving $50 million in state funds for.

article thumbnail

FTC, in unusual move, leads Sanofi to terminate a drug research deal

BioPharma Drive: Drug Pricing

Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AltruBio lands up to $225M after shift to immune drug research

BioPharma Drive: Drug Pricing

Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

article thumbnail

Vera drug scores in closely watched study in rare kidney disease

BioPharma Drive: Drug Pricing

Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year.

Disease 177
article thumbnail

Pfizer, looking for a jumpstart, leans into cancer drug research

BioPharma Drive: Drug Pricing

Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.

article thumbnail

Foundery, a new biotech venture firm, sets out to speed early immune drug research

BioPharma Drive: Drug Pricing

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Research 246
article thumbnail

BioAge prices $198M IPO, validating pivot to obesity drug research

BioPharma Drive: Drug Pricing

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.